We are committed to helping people with neurodegenerative disorders through innovative research and development.
Capital Markets Day 2025
Capital Markets Day 2025
The live stream will start on June 2, 2025 at 10.30 CEST — Live from Helio GT 30, Grev Turegatan 30, Stockholm
February 13, 2025
Full Year Report 2024
The fourth-quarter report for October – December 2024 was published on Thursday, February 13, 2025, at 08:00 a.m. CET.
Audiocast with teleconference: at 09:30 CET the same day.
Our Therapeutic Areas of Expertise
We are developing disease modifying treatments against Alzheimer’s disease. Lecanemab is an antibody targeting oligomers and protofibrils, the harmful forms of Aβ.
Due to the wide spread and severity of the disease, combined with a lack of effective pharmaceutical drugs, the need for new and effective treatments is significant.
ALS – Amyotrophic lateral sclerosis
Current treatments include drugs that slow down the disease development or relieve severe symptoms. BioArctic aims for targeting the cause of nerve cell damage.
The blood-brain barrier controls the passage of substances between the bloodstream and the brain. It protects the brain, but can make it difficult to deliver drugs to the brain.
This is BioArctic
BioArctic is a Swedish research oriented biopharma company. Based on our cutting-edge expertise in neurodegenerative disorders, we have built a broad and well-diversified project portfolio with the potential to improve the health of patients. The diversity of projects in various phases of development provides a solid basis for creating value for patients, their families, and society as a whole. This makes us an attractive company to both partners and investors.
Our progress in numbers
-
20
years of world leading research
-
15
research projects
-
5
cooperation principles
Investor contact
